Skip to content

New Technologies in Oral Reconstructive Medicine

Consensus from the
AAP/SEPA/Osteology Workshop 

Why this consensus matters

Oral reconstructive medicine is entering a new phase. Advances in scaffolds, biologics, cell therapies, digital workflows, and artificial intelligence are reshaping how clinicians approach hard- and soft-tissue regeneration around teeth and dental implants.

This workshop brought together leading international experts to assess what is already supported by evidence, what remains emerging, and how these technologies may improve patient outcomes, reduce morbidity, and enable more personalized regenerative care.

Quick facts

about the meeting

3 leading organizations

 A unique collaboration between the Osteology Foundation, the AAP (American Academy of Periodontology), and the Sepa (Spanish Society of Periodontology). 

International expert consensus

 42 experts from North America, Europe, and Australia collaborated to define the future of oral reconstructive medicine. 

3 Working groups Three expert groups examined scaffolds, biologics and cells, and emerging personalized approaches to build a complete view of new technologies in oral reconstructive medicine.
Evidence-based foundation

 The consensus was informed by 5 commissioned systematic reviews, providing a robust scientific basis for every recommendation. 

First look at AI in regenerative dentistry

 One of the first international consensus reports to explicitly discuss the role of artificial intelligence and personalized medicine in regenerative therapies. 

6 reasons to read the consensus report

 

The Consensus workshop leads comment on the workshop outcomes.

Hover over each card to access additional related resources (requires login), or scroll further to access the full articles.

Jose Nart-living-BG
Learn more about soft tissue graft materials
José NartLead of Working Group 1

“Soft tissue substitutes, sometimes for some specific circumstances, work as well as our patient’s own tissue.”

Learn more about soft tissue graft materials
Frank Schwarz_living-BG Large
Listen about the patient role
Frank SchwarzLead of Working Group 1

“The patient is in the center… we are actually talking about customized scaffolds that can be used for more advanced defects.”

Listen about the patient role
Hom-Lay Wang-living BG
More on biologics for soft tissue augmentation
Hom-Lay WangLead of Working Group 2

“Basically, the evidence is there and very promising. We need more randomized controlled trials, but initial data show they [biologics] are safe, they are a good approach, and they may offer a promising future in terms of how we correct these defects.”

More on biologics for soft tissue augmentation
Mariano Sanz-living BG
Read the paper of Working Group 2
Mariano SanzLead of Working Group 2

“We are focusing on what we can add in terms of new technologies to make the current alternatives work better, improve our predictability, and perhaps overcome some of the barriers we have with current therapies, mainly in large bone defects.”

Read the paper of Working Group 2
Will Giannobile
Read more about digital technologies in oral tissue regeneration
William GiannobileLead of Working Group 3

“One of the exciting aspects is using AI-enabled technologies that can really help identify the characteristics of how the defects are shaped in the patient's mouth… and then these particular scaffolds or replacements can be designed that fit very closely to the patient's architecture of the defects.”

Read more about digital technologies in oral tissue regeneration
Saso Ivanovski
Learn more
Saso IvanovskiLead of Working Group 3

“The two major areas we covered and the most exciting areas are personalised scaffolds and emerging technologies.”

Learn more